Peptide Comparison
BPC-157 vs CJC-1295 + Ipamorelin: How They Differ
They're both compounded peptides — but they're in different categories, with different mechanisms, different goals, and different evidence bases.
At a glance
| — | BPC-157 | CJC-1295 + Ipamorelin |
|---|---|---|
| Category | Regenerative / tissue repair | Growth-hormone secretagogue |
| Primary goal | Tendon, ligament, gut healing | Sleep, recovery, body composition |
| Mechanism | Pentadecapeptide; angiogenic and cytoprotective effects | Stimulates endogenous GH release via pituitary |
| Route | Subcutaneous or oral | Subcutaneous, usually at bedtime |
| Evidence base | Strong preclinical, early human | Decades of clinical use as GH secretagogues |
| Current U.S. status | On do-not-compound list | On do-not-compound list |
Different categories, different problems
The most common mistake patients make is treating BPC-157 and CJC-1295 + ipamorelin as substitutes. They are not. BPC-157 is a regenerative peptide — its job is local tissue repair. CJC-1295 + ipamorelin is a growth-hormone secretagogue — its job is to lift endogenous GH pulses to restore what the pituitary produced a decade earlier. They target different biology, different symptoms, and different timelines. A patient with Achilles tendinopathy is not helped by GH secretagogues. A 45-year-old with poor sleep, slow recovery, and central adiposity is not helped by BPC-157. Picking the right tool starts with the right diagnosis.
Mechanism deep-dive
BPC-157 is a synthetic 15-amino-acid fragment (pentadecapeptide) derived from a protective sequence found in human gastric juice. Its documented mechanisms include: (1) upregulation of VEGF receptor 2, driving angiogenesis at injury sites; (2) modulation of nitric oxide synthase and dopaminergic/serotonergic tone; (3) protection of endothelial and epithelial cells against oxidative and inflammatory stress; (4) accelerated tendon-to-bone and muscle repair in preclinical models (Chang 2011, Sikiric 2018). Human clinical data is limited but growing, especially in tendinopathy and IBD-adjacent gut issues.
CJC-1295 + ipamorelin is a two-peptide combination. CJC-1295 (without DAC in most compounded protocols) is a GHRH analog — it binds pituitary GHRH receptors and stimulates GH release. Ipamorelin is a selective ghrelin/GHS-R1a agonist that adds a second, complementary GH pulse without stimulating cortisol or prolactin (a key differentiator from earlier secretagogues like GHRP-6). Combined, they produce a physiologic GH pulse that mimics youthful nocturnal secretion, without the supraphysiologic exposure of recombinant HGH.
Evidence base compared
- BPC-157: Robust preclinical (rodent) evidence across tendon, ligament, muscle, gut, and CNS injury models. Early human case series in tendinopathy and IBD, but no phase III trials. Anecdotal clinical use in sports medicine is extensive; RCT-grade evidence in humans is what regulators are asking for.
- CJC-1295 + ipamorelin: Both molecules individually have decades of pharmacokinetic and safety data. GHRH analogs are FDA-approved for pediatric GH deficiency (in different molecular forms). Adult use in longevity/body-composition medicine is off-label but well-characterized biochemically.
Timeline of effect
- BPC-157: Tissue-repair effects generally appear at 4–8 weeks. Gut-symptom effects can appear within 2–3 weeks.
- CJC-1295 + ipamorelin: Improved slow-wave sleep and recovery within 1–2 weeks. IGF-1 rises within 4 weeks. Body-composition and skin/hair effects at 3–6 months.
Side-effect profiles
- BPC-157: Well-tolerated in preclinical and available human data. Injection-site reactions possible. No documented systemic toxicity signals to date. Long-term human data is thin.
- CJC-1295 + ipamorelin: Water retention, mild appetite increase, tingling/numbness (paresthesias), rare headache. Contraindicated in active malignancy, uncontrolled diabetes, and severe insulin resistance. Requires baseline IGF-1 and periodic monitoring.
Contraindications you cannot ignore
- Active or recent (< 5 years) malignancy — a hard stop for GH secretagogues.
- Pregnancy or lactation — do not use either peptide.
- Uncontrolled diabetes (HbA1c > 8) — GH secretagogues worsen insulin resistance.
- Severe cardiac disease — discuss with cardiology before either peptide.
Choosing between them
If your primary problem is injury or slow tissue healing — tendinopathy, post-surgical repair, chronic ligament strain, or GI mucosal irritation — BPC-157 is the appropriate tool if compounding access permits. Full BPC-157 guide →
If your primary problem is midlife decline in recovery, sleep, and body composition — poor sleep quality, longer recovery from workouts, loss of lean mass, central weight gain despite training — CJC-1295 + ipamorelin is the appropriate tool. Full CJC-1295 + ipamorelin guide →
Regulatory context (2026)
Both peptides are currently on the FDA "do not compound" list, meaning 503A pharmacies cannot legally compound them for U.S. patients pending PCAC review. The July 2026 Pharmacy Compounding Advisory Committee meeting is reviewing both. Access depends on the outcome. See FDA peptide review 2026 and is BPC-157 legal? for the current legal landscape.
Sources
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 as therapy. Curr Med Chem 2018.
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998.
Frequently asked questions
Can you take BPC-157 and CJC-1295 together?
They have different mechanisms and no known direct interaction. Combination protocols may be appropriate in some patients under physician supervision, but they should not be combined without evaluation.
Which works faster?
CJC-1295 + ipamorelin shows sleep and recovery effects in 1–2 weeks; body-composition changes take 3–6 months. BPC-157 tissue-healing effects are typically measured at 4–8 weeks.
Are either FDA-approved?
No. Both are currently on the FDA do-not-compound list pending review at the July 2026 PCAC meeting.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.